Cohance Lifesciences Limited (BOM:543064)

Market Cap	336.89B
Revenue (ttm)	12.59B
Net Income (ttm)	2.41B
Shares Out	n/a
EPS (ttm)	9.40
PE Ratio	139.57
Forward PE	52.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,957
Average Volume	8,999
Open	895.95
Previous Close	870.25
Day's Range	864.00 - 895.95
52-Week Range	856.90 - 1,359.00
Beta	n/a
RSI	33.64
Earnings Date	Aug 8, 2025

About Cohance Lifesciences

Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research services. It also manufactures finished dosage formulations for pharmaceutical companies; and specialty chemicals, such as electronic chemicals. The company ...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,193
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.